EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network

Ines Esparragosa Vazquez, Marc Sanson, Olivier L Chinot, Maxime Fontanilles, Romain Rivoirard, Laure Thomas-Maisonneuve, Stéphanie Cartalat, Emeline Tabouret iD, Romain Appay, Alice Bonneville-Levard, Amélie Darlix, David Meyronet iD und 8 weitere

Neuro-Oncology Advances · 01.01.2024 · 6 (1)

DOI: 10.1093/noajnl/vdae078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 27.05.2024. Verfasst von Ines Esparragosa Vazquez und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, East Group Hospital, Hospices Civils de Lyon, Lyon, France. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Based on preclinical studies showing that IDH-mutant (IDHm) gliomas could be vulnerable to PARP inhibition we launched a multicenter phase 2 study to test the efficacy of olaparib monotherapy in this population.

Methods

Adults with recurrent IDHm high-grade gliomas (HGGs) after radiotherapy and at least one line of alkylating chemotherapy were enrolled. The primary endpoint was a 6-month progression-free survival rate (PFS-6) according to response assessment in neuro-oncology criteria. Pre-defined threshold for study success was a PFS-6 of at least 50%.

Results

Thirty-five patients with recurrent IDHm HGGs were enrolled, 77% at ≥ 2nd recurrence. Median time since diagnosis and radiotherapy were 7.5 years and 33 months, respectively. PFS-6 was 31.4% (95% CI [16.9; 49.3%]). Two patients (6%) had an objective response and 14 patients (40%) had a stable disease as their best response. Median PFS and median overall survival were 2.05 and 15.9 months, respectively. Oligodendrogliomas (1p/19q codeleted) had a higher PFS-6 (53.4% vs. 15.7%, P = .05) than astrocytomas while an initial diagnosis of grade 4 astrocytoma tended to be associated with a lower PFS-6 compared to grade 2/3 gliomas (0% vs 31.4%, P = .16). A grade 2 or 3 treatment-related adverse event was observed in 15 patients (43%) and 5 patients (14%), respectively. No patient definitively discontinued treatment due to side effects.

Conclusions

Although it did not meet its primary endpoint, the present study shows that in this heavily pretreated population, olaparib monotherapy was well tolerated and resulted in some activity, supporting further PARP inhibitors evaluation in IDHm HGGs, especially in oligodendrogliomas.

Schlagwörter

Stichwörter der Autor:innen

IDHclinical trialhigh-grade gliomasolaparib

Autor:innen und Institutionen

  • Department of Neuro-Oncology, East Group Hospital, Hospices Civils de Lyon, Lyon, France.
  • Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France.
  • Service de Neurologie 2, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France.
  • Aix-Marseille University, CNRS, Inst Neurophysiopathol, Marseille, France.
  • Department of Neuro-Oncology, AP-HM, University Hospital Timone, Marseille, France.
  • Department of Medical Oncology, Cancer Centre Henri Becquerel, Rouen, France.

ORCID-Profile: Emeline Tabouret, David Meyronet, Marc Barritault, François Ducray

Zitieren

APA

Esparragosa Vazquez, I., Sanson, M., Chinot, O. L., Fontanilles, M., Rivoirard, R., Thomas-Maisonneuve, L., Cartalat, S., Tabouret, E., Appay, R., Bonneville-Levard, A., Darlix, A., Meyronet, D., Barritault, M., Gueyffier, F., Remontet, L., Maucort-Boulch, D., Honnorat, J., Dehais, C., Ducray, F., & POLA Network (2024). Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network. Neuro-Oncology Advances, 6(1). https://doi.org/10.1093/noajnl/vdae078

Vancouver

Esparragosa Vazquez I, Sanson M, Chinot OL, Fontanilles M, Rivoirard R, Thomas-Maisonneuve L, et al. Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network. Neuro-Oncology Advances. 2024;6(1). doi:10.1093/noajnl/vdae078

BibTeX
@article{EsparragosaVazquez2024,
  author = {Esparragosa Vazquez, Ines and Sanson, Marc and Chinot, Olivier L and Fontanilles, Maxime and Rivoirard, Romain and Thomas-Maisonneuve, Laure and Cartalat, Stéphanie and Tabouret, Emeline and Appay, Romain and Bonneville-Levard, Alice and Darlix, Amélie and Meyronet, David and Barritault, Marc and Gueyffier, François and Remontet, Laurent and Maucort-Boulch, Delphine and Honnorat, Jérôme and Dehais, Caroline and Ducray, François and POLA Network, POLA Network},
  title = {Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network},
  journal = {Neuro-Oncology Advances},
  year = {2024},
  volume = {6},
  number = {1},
  doi = {10.1093/noajnl/vdae078}
}
Kostenlos starten →